TRILEPTAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRILEPTAL (TRILEPTAL).
Trileptal (oxcarbazepine) stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting repetitive firing of action potentials. It also modulates high-voltage-activated calcium channels and increases potassium conductance.
| Metabolism | Oxcarbazepine is extensively metabolized via cytosolic enzymes to its active metabolite 10-monohydroxy derivative (MHD). MHD is further conjugated with glucuronic acid. Hydroxylation and conjugation are the primary pathways. CYP450 enzymes play a minor role. |
| Excretion | Renal excretion is the primary route; 95% of the dose is excreted in urine (79% as MHD, 20% as MHD conjugates, <1% as unchanged oxcarbazepine), and 4% in feces. |
| Half-life | Parent oxcarbazepine: 1.3–2.3 hours; active metabolite MHD: 8–11 hours (monohydroxy derivative); clinically, the long MHD half-life supports twice-daily dosing. |
| Protein binding | Oxcarbazepine: ~60% bound to serum proteins (mainly albumin); MHD: ~40% bound; binding is independent of drug concentration. |
| Volume of Distribution | Vd: 2.4 L/kg (for MHD), indicating extensive tissue distribution. |
| Bioavailability | Oral: >95% bioavailability as parent drug; rapidly and extensively metabolized to MHD (first-pass effect minimal, MHD is the active moiety). |
| Onset of Action | Oral: time to peak concentration 4–6 hours (MHD); antiepileptic effect typically within 1–2 days of starting therapy. |
| Duration of Action | Approximately 12 hours due to MHD half-life; steady-state achieved within 2–3 days with twice-daily dosing. |
Adults: 600 mg orally twice daily initially; titrate by 600 mg/day every week. Maintenance: 600-1200 mg twice daily.
| Dosage form | TABLET |
| Renal impairment | Creatinine clearance <30 mL/min: start with 150 mg orally twice daily; titrate slowly. ClCr 30-49 mL/min: start with 300 mg twice daily. ClCr ≥50 mL/min: no adjustment. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): reduce initial dose by 50% and titrate more slowly. Child-Pugh C: use with caution; no specific guidelines. |
| Pediatric use | Children (2-16 years): initial 8-10 mg/kg/day in two divided doses; maximum 600 mg/day. Titrate weekly by 8-10 mg/kg/day; target maintenance 20-30 mg/kg/day (max 1200 mg/day). For monotherapy: 300 mg/day initially, titrate by 300 mg/day every 2 days. |
| Geriatric use | Start at lower doses (300-450 mg/day) and titrate slowly; monitor renal function; adjust based on creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRILEPTAL (TRILEPTAL).
| Breastfeeding | Excreted in breast milk; M/P ratio ~0.5. Infant serum levels are low (4-10% maternal). Consider benefits versus risks. Monitor for sedation, poor feeding, and weight loss in the infant. |
| Teratogenic Risk | Major congenital malformations, particularly neural tube defects and major birth defects, increase in first trimester exposure (RR ~2.4). Risk for craniofacial, cardiac, and hypospadias defects. Second/third trimester: risk of neurodevelopmental deficits (reduced IQ, autism spectrum). Neonatal hemorrhage due to vitamin K deficiency and withdrawal syndrome (irritability, feeding difficulties) can occur. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to oxcarbazepine or any component of the formulation","History of hypersensitivity to carbamazepine (cross-sensitivity)"]
| Precautions | ["Clinically significant hyponatremia (sodium <125 mmol/L) can develop within days to months; consider monitoring serum sodium in patients at risk (e.g., elderly, those on diuretics).","Hypersensitivity reactions including anaphylaxis and angioedema have been reported.","Cross-sensitivity with carbamazepine: risk of serious dermatologic reactions (e.g., Stevens-Johnson syndrome) in patients with HLA-B*1502 allele (Asian ancestry).","Suicidal behavior and ideation have been observed; monitor for emergence or worsening of depression.","Dizziness, somnolence, and ataxia may occur, especially during titration; caution with activities requiring alertness.","May reduce efficacy of oral contraceptives; advise non-hormonal contraception.","Withdrawal seizures on abrupt discontinuation; taper dose."] |
Loading safety data…
| Fetal Monitoring | Preconception high-dose folic acid (4-5 mg/day). First trimester ultrasound and echocardiography at 18-22 weeks. Offer maternal serum alpha-fetoprotein screening. Serial growth scans in third trimester. Monitor for maternal hepatitis, pancreatitis, and hyponatremia with sodium levels every 1-3 months. Postnatal: vitamin K administration to neonate, monitor for withdrawal. |
| Fertility Effects | May disrupt menstrual cycle and reduce ovulation due to enzyme induction affecting sex hormone metabolism; no direct evidence of impaired fertility. In males, transient decreases in sperm count and motility reported; considered reversible. |